
RESEARCH



Traditional medicine users in a treated chronic disease population: a cross-sectional study in Indonesia

Ivan Surya Pradipta^{1,2*†}, Kevin Aprilio^{1,2†}, Raden Maya Febriyanti³, Yozi Fiedya Ningsih^{1,2}, Mochammad Andhika Aji Pratama², Raden Bayu Indradi³, Vesara Ardhe Gatera⁴, Sofa Dewi Alfian^{1,2}, Aulia Iskandarsyah⁵ and Rizky Abdulah^{1,2}

Abstract

Background Traditional medicine (TM) is commonly used as a treatment in Indonesia. This raises the need for an analysis of its potential development and irrational use. Therefore, we analyze the proportion of TM users among chronic disease patients and its associated characteristics to optimize the use of TM in Indonesia.

Methods A cross-sectional study of treated adult chronic disease patients was conducted using the fifth Indonesian Family Life Survey (IFLS-5) database. Descriptive analysis was used to identify the proportion of TM users, while a multivariate logistic regression was used to analyze their characteristics.

Results This study included 4901 subjects and identified 27.1% as TM users. The highest TM use was in subjects with cancer (43.9%), liver issues (38.3%), cholesterol issues (34.3%), diabetes (33.6%), and stroke (31.7%). Characteristics associated with TM users were a perception of one's current health as unhealthy (OR 2.59, 95% CI 1.76–3.81), low medication adherence (OR 2.49, 95% CI 2.17–2.85), age above 65 years (OR 2.17, 95% CI 1.63–2.90), having higher education (OR 1.64, 95% CI 1.17–2.29), and residence outside of Java (OR 1.27, 95% CI 1.11–1.45).

Conclusions Low medication adherence among TM users highlights the potentially irrational use of treatment in chronic diseases. Nevertheless, the longstanding use of TM users indicates the potential for its development. Further studies and interventions are needed to optimize TM use in Indonesia.

Keywords Traditional medicine, Chronic disease, Patient characteristic, Rational drug use

[†]Ivan Surya Pradipta and Kevin Aprilio contributed equally to this work.

⁴ Department of Pharmacy and Health Sciences, Universiti Kuala Lumpur -

Padjadjaran, Jalan Ir. Soekarno KM. 21, Jatinangor, Sumedang, West Java 45363, Indonesia



© The Author(s) 2023, corrected publication 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence:

Ivan Surya Pradipta

ivanpradipta@unpad.ac.id

¹ Department of Pharmacology and Clinical Pharmacy, Faculty

of Pharmacy, Universitas Padjadjaran, Jalan Ir. Soekarno KM. 21,

Jatinangor, Sumedang, West Java 45363, Indonesia

² Drug Utilization and Pharmacoepidemiology Research Group, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jalan Ir. Soekarno KM. 21, Jatinangor, Sumedang,

West Java 45363, Indonesia ³ Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jalan Ir. Soekarno KM. 21, Jatinangor, Sumedang, West Java 45363, Indonesia

Royal College of Medicine Perak, Ipoh, Perak, Malaysia ⁵ Department of Clinical Psychology, Faculty of Psychology, Universitas Padjadjaran, Jalan Ir. Soekarno KM. 21, Jatinangor, Sumedang, West Java

Introduction

Despite the expansion of modern medicine—and the general improvement in its quality [1]—traditional medicine (TM) is still commonplace in various parts of the world. In 2018, the World Health Organization (WHO) reported that 88% of its 194 member states acknowledge using traditional, complementary, and alternative medicine [2]. While the use of herbal medicine has been increasing in several developed countries, such as the United States [3], its use in developing countries has generally reached a "steady state" where it coexists with modern medicine, even in urban areas [4].

The knowledge and use of TM have been increasing in light of the COVID-19 pandemic [5]. With the pressure the COVID-19 pandemic has imposed on public health— and the increase in TM use—it can be seen that despite the merits traditional herbal medicine offers in terms of treating COVID-19 [6], its use outside the modern medicine system indicates its role as a substitute for quality healthcare within the context of health-seeking behavior [7, 8], mainly due to various issues inherently related to self-medication with herbal medicines [9–11].

The longstanding use of TM has also led to its prominence in societies such as Indonesia [12]. Among the multiplicity of Indonesian traditional medical systems [9], *jamu* is one of the TM generally used in Indonesia [13]. Historically, the term *jamu* stems from Javanese language meaning traditional medicine from plants, minerals, animal parts, or extracts thereof [12]. *Jamu* is now used to generally describe herbal TM of Indonesian origin [12].

TM in the forms of herbal medicine has also been the main concern of Indonesian government [14]. Indonesian government, through its *Badan Pengawas Obat dan Makanan*, has classified herbal medicine into three classifications based its level of evidence: (1) *jamu* as herbal preparations based solely on its empirical evidence; (2) *obat herbal terstandar* (*lit.* standardized herbal medicine) as herbal preparations that have undergone preclinical trials for its safety; and (3) *fitofarmaka* (*lit.* phytomedicine) as herbal preparations that undergone clinical trials for its efficacy [15].

However, despite efforts by the Indonesian government to regulate TM use [16–18], TM is still commonly used freely outside of the formal medical system [13]. Regardless of TM's economic value [19, 20], the lack of scientific evidence in most of TM has prevented its clinical use and integration into the modern medical system, hence posing possibilities for its irrational use [21–24].

Multiple factors contribute to the use of TM, such as perceived illness, demographic and socioeconomic factors, and communication systems [25-27]. Such characteristics correlated with the use of TM can be assumed

to arise as the result of social dynamics that influence people's health-seeking behavior. Therefore, the population of TM users can then be used as a proxy to identify groups who are underserved by modern medicine and seek access to traditional herbal medicine as an alternative [28].

A previous study in Indonesia indicated that having a chronic disease is associated with the use of TM [26]. Furthermore, the dependence of people with chronic diseases on long-term treatment, particularly medications, can be assumed to provide a baseline of interpretation regarding the use of TM in society [29]. The length of such diseases should also provide consistent data regarding the use of TM, leading to the interest in studying this phenomenon among chronic disease patients.

Although previous smaller-scale studies have analyzed characteristics of TM users [25–27], the evaluation of such phenomena has been lacking in the context of its relevance to medicine development and its rational use, particularly juxtaposed to the treatment process of chronic disease. With the issues surrounding the current treatment modalities for chronic disease [30], it is essential to identify the real-world conditions of TM users. Therefore, we analyze the proportion and characteristics of TM users in patients with chronic diseases to optimize the use of TM in Indonesia.

Methods

Study design and participants

This study was based on the fifth Indonesian Family Life Survey (IFLS-5) database. The IFLS-5 data were obtained from a survey conducted from 2014 to 2015 by RAND Labor and Population in collaboration with Universitas Gadjah Mada [31]. The RAND Corporation, the initiator of IFLS-5, is a policy institute based in Santa Monica, CA, USA [32]. The IFLS-5 survey was performed on approximately 75,000 populations spread over 27 Indonesian provinces, representing approximately 83% of the Indonesian population [33]. The survey was performed using multistage stratified sampling by selecting a random household member from a random household in each enumeration area [33].

In this study, subjects were selected from the IFLS-5 database, with the criterion being chronic disease patients undergoing any type of treatment. Subjects with incomplete data were excluded. Subsequently, subjects were divided into TM users and non-TM users based on observation of the outcome variable as mentioned below.

Variables and measures

The exposure variables were selected based on the factors of health-seeking behavior that exist in the IFLS-5 database [34]. Relevant variables were divided into two main factors: sociodemographic factors and patient-related factors. Sociodemographic factors include sex, annual income, wealth index, ethnicity, residential area, and insurance ownership. Patient-related factors include education level, smoking behavior, working days missed in a month, current self-perceived health status, and medication adherence.

The outcome variable was defined as treatments used by subjects for their chronic disease. This was obtained on a self-reported basis through the question *"Has a doctor/paramedic/nurse/midwife ever told you that you had [types of chronic disease]?"* (Book IIIB/CD05) [33]. The subsequent question, *"Are you taking [types of medication] to treat [types of chronic disease] and its complications?"* (Book IIIB/CD09a) was posed to each chronic disease subject [33].

Non-TM users were classified as subjects who solely used modern medicine—i.e., pharmacological and nonpharmacological treatments, including radiotherapy, physical/occupational therapy, and psychological therapy. TM users were classified as subjects who reported TM use for their chronic disease, solely or in conjunction with modern medicine. Further details on the operational definition of this study can be found in Table S1.

Data analysis

A descriptive analysis was performed to describe the proportion of subjects' characteristics, types of chronic disease, and use of traditional or non-TM. A bivariate logistic analysis was used to determine variables potentially used in the multivariate analysis by the cutoff value of p < 0.25. The variance inflation factor (VIF) was further analyzed to eliminate multicollinearity. A subsequent multivariate logistic analysis with the enter step was used to analyze the characteristics of TM users. The significance of each exposure variable was determined by a cut-off value of p < 0.05 and a 95% confidence interval (95% CI).

All statistical analyses were performed using SPSS[®] Statistics for Windows[™] version 26 from IBM[®] Corporation (Armonk, NY, USA). The results of this study were then reported following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology Statement) guidelines for cross-sectional study (Table S2) [35].

Results

A total of 4,912 subjects from the IFLS-5 database were found to have the chronic disease(s) being treated. Among them, 11 subjects (0.05%) had missing data; 4901 subjects were finally included for further analysis. The




Fig. 1 Flow diagram of included subjects

flow diagram of the included subjects is presented in Fig. 1.

The predominant characteristics of the population of this study are subjects aged 25–65 years (74.9%), nonsmokers (67.9%), female sex (61.3%), and non-Javanese ethnicity (55%). Subjects who resided in Java dominated the study (58,6%) and most also lived in urban locations (64.6%). As many as 27.1% of subjects were found to use TM. These subjects' characteristics are presented in Table 1.

Chronic diseases such as cancer (43.9%), liver issues (38.3%), cholesterol issues (34.3%), diabetes (33.6%), and stroke (31.7%) had the highest number of TM users by proportion. This contrasts with chronic diseases such as memory issues (17.6%), digestive issues (24.5%), other lung issues (24.7%), hypertension (26.4%), and psychiatric issues (26.7%), which had the lowest number of TM users by proportion. The proportion of TM users in each chronic disease is presented in Fig. 2.

In the multivariate analysis, all variables used in this analysis exhibited no multicollinearity by having a value of VIF < 10 (Table S3). It was identified that subjects with poor health perception (OR 2.59, 95% CI 1.76–3.81), low medication adherence (OR 2.49, 95% CI 2.17–2.85), >65 years of age (OR 2.17, 95% CI 1.63–2.90), having higher education (OR 1.64, 95% CI 1.17–2.29), and residence outside of Java (OR 1.27, 95% CI 1.11–1.45) were more likely to use TM. A lower perception of one's health, poor medication adherence, and older age were the most significant variables contributing to the use of TM. The multivariate analysis is presented in Table 2.

Table 1 Subject characteristics (n = 4,901)

No	Characteristics	Proportion (%)
1	Socioeconomic factors	
	Male ^a	38.7%
	Age (years)	
	15–24	8.3%
	25–65	74.9%
	>66	16.8%
	Annual income (IDR) ^a	
	>40 million	7.9%
	12–40 million	20.6%
	<12 million	32.4%
	Not working	38.3%
	Wealth index ^a	
	Quintile 5	24.5%
	Quintile 4	18.9%
	Quintile 3	22.4%
	Quintile 2	18.9%
	Quintile 1	14.9%
	Non-Javanese ethnicity ^a	55.0%
	Non-Java residence ^a	41.4%
	Rural residence ^a	35.4%
	No insurance ownership ^a	44.3%
2	Patient-related factors	
	Education	
	Unschooled	8.0%
3	Elementary	35.9%
	Junior high	16.1%
	Senior high	25.4%
	Higher education	13.9%
	Smoking behavior	
	Non-smoker	67.9%
	Ex-smoker	10.1%
	Active smoker	22.0%
	Active days missed in a month ^a	
	0	37.3%
	1–7	47.0%
	>7	15.6%
	Current self-related health status	
	Very healthy	8.6%
	Somewhat healthy	45.8%
	Somewhat unhealthy	40.7%
	Very unhealthy	4.8%
	Took no medications in the past week	44.3%
	Traditional medicine users	27.1%

^a missing value: Sex 1 (0.0%), Education 36 (0.7%), Annual income 38 (0.8%), Wealth index 22 (0.4%), Ethnicity 22 (0.4%), Geographical residence 1 (0.0%), Demographical residence 1 (0.0%), Insurance ownership 20 (0.4%), Active days missed in a month 4 (0.1%)

Discussion

This study found that older age, non-Java residence, higher education, poor self-perceived health status, and nonadherence to prescribed medication are associated with TM use. These findings highlight that knowledge (education level and age), access (geographical residence), and perception of health (self-perceived health status and medication adherence) are the three main factors associated with the use of TM. The characteristics found in this study may explain the social phenomena and conditions surrounding chronic disease treatment in Indonesia. It can be a guide to identify potential problems and strategies to optimize the benefits of TM use.

Knowledge

In our study, knowledge was associated with the utilization of TM. It refers to the knowledge of their illness and the treatment available. This concept is in line with the health-seeking behavior theory that the pursuit of treatment is largely driven by perception and knowledge of illness [8, 36].

A previous study showed that the association between increasing use of TM and education levels indicates the correlation between health knowledge and the options of treatment modalities for such diseases [37]. As TM in Indonesia is used empirically, information regarding it is disseminated through daily social functions [37]. Harahap et al. also indicated a similar finding in the form of higher self-medication rates among patients with higher education [38].

The association of TM use with increased age should also be seen as an indicator of one's knowledge of TM. The increasing need for healthcare with age leads to an increase in exposure to medicine—including TM—and therefore increases one's knowledge of the traditional means of treatment available for the condition [37]. This process is also in line with the general tendency of chronic diseases to have their onset in later stages of one's life.

While the use of TM may indicate patients' better knowledge, the self-obtained nature of TM knowledge may pose problems [39]. The lack of assessment from a healthcare professional may lead to phenomena such as healer shopping [40], causing issues related to treatment fragmentation [41]. In this regard, the use of TM poses potential treatment irrationality through the possible intervention of the treatment process at large as well as improper use of the TM itself.

Access

Despite efforts by the Indonesian government to overcome the disparity between Indonesian regions, the




Fig. 2 Distribution of treatments across chronic diseases

problem of economic and development disparity can still be seen [42]. In healthcare, this problem presents itself in various forms, such as the lower rate of utilization of outpatient care facilities in rural areas [43]. While this study does not show a discrepancy in TM use across demographical residences, the difference in TM use between Java and other Indonesian areas should indicate problems in access to health facilities and modern medicine due to geographical development disparity [44].

In such a sense, the persisting use of TM may further indicate a larger issue regarding the formal medical system itself, as signified by Alkaff et al. [30]. Therefore, it can be assumed that issues regarding healthcare access in the Indonesian context are related to the medical system itself, particularly owing to the increasing public healthcare coverage in Indonesia by BPJS Kesehatan [45]. The phenomenon may also signify other factors influencing the use of TM, i.e., cultural factors.

Health perception

A study by Widayanti et al. concluded that, within the context of multiple medical systems in Indonesia [46], the perception of the medical system was among the main factors influencing the treatment of choice [9]. This aspect is most apparent in the association of TM use with treatment nonadherence, as one of the fundamental issues in treatment irrationality. Additionally, the role of perception also emerged from the association of low self-perceived health status to TM use without the impairment of a health condition (as measured in working days missed in a month). This shows the significance

of subjectivity and perception of sickness within the context of health-seeking behavior [8].

A study by Iskandasryah et al. revealed that TM use was associated with a lower perception of one's health condition and eventually with patients' treatment adherence [47], confirming the association of lower adherence to TM use. However, it should also be noted that patients' difficulties in accessing modern medicine, which often causes which causes its substitution with the more easily accessible TM [7], may also lead to treatment nonadherence.

The role TM plays in building health perception raises its potential for development. While being commonly used as a substitution for modern medicine [48], the empirical basis of various TM use—for instance, *jamu*—is mostly yet to be clinically confirmed as a relatively safe and effective means of treatment [49]. Therefore, the acceptance of *jamu* in the formal medical system through scientific research and evidence should be developed to widen access to TM in treatment and reduce its potential irrational use.

Study strengths and limitations

The self-reported data in this study might pose recall and social-desirability biases. Furthermore, the inferential nature of this study, using secondary data obtained through structured questionnaires, may pose a reduction of perceived phenomena that would require further study through qualitative means. Due to the limited data in the database, this study did not consider variables that may affect the study outcome, such as

No	Variables	Non-traditional medicine users (n = 3,573)	Traditional medicine users (n = 1,328)	Bivariate		Multivariate		
				Odds ratio (95% CI)	<i>p</i> -value	Odds ratio (95% CI)	<i>p</i> -value	
1	Socioeconomic factors							
	Male	1324	572	1.29 (1.13–1.46)	0.000*	1.08 (0.88–1.31)	0.462	
	Age (years)							
	15–24	336	71	Reference				
	25–65	2615	1055	1.54 (1.14–2.08)	0.005*	1.82 (1.30–2.56)	0.001**	
	>65	622	202	1.91 (1.46–2.49)	0.000*	2.17 (1.63–2.90)	0.000**	
	Annual income (IDR)							
	>40 million	262	126	Reference				
	12–40 million	714	296	0.68 (0.54–0.87)	0.002*	0.96 (0.72–1.27)	0.751	
	< 12 million	1157	432	0.78 (0.61–0.99)	0.038*	0.93 (0.70–1.23)	0.612	
	No income	1413	463	0.86 (0.67–1.11)	0.248*	0.91 (0.69–1.20)	0.481	
	Wealth index							
	Quintile 5	866	334	Reference				
	Quintile 4	663	263	1.03 (0.85–1.25)	0.772	1.05 (0.86–1.28)	0.624	
	Quintile 3	797	303	0.99 (0.82–1.19)	0.878	0.99 (0.82–1.20)	0.930	
	Quintile 2	673	253	0.98 (0.81–1.18)	0.794	1.01 (0.82–1.24)	0.924	
	Quintile 1	557	170	0.79 (0.64–0.98)	0.031*	0.83 (0.66–1.04)	0.103	
	Non-Javanese ethnicity	1957	737	1.03 (0.91–1.17)	0.674	Not Included		
	Non-Java residence	1414	616	1.32 (1.16–1.50)	0.000*	1.27 (1.11–1.45)	0.001**	
	Rural residence	1247	489	1.08 (0.95–1.24)	0.214*	1.03 (0.89–1.20)	0.663	
	No insurance ownership	1565	607	1.09 (0.96–1.23)	0.204*	1.10 (0.96–1.26)	0.183	
2	Patient-related factors							
	Education							
	Unschooled	301	89	Reference				
	Elementary	1294	465	1.22 (0.94–1.58)	0.140*	1.15 (0.87–1.51)	0.337	
	Junior high	585	203	1.17 (0.88–1.56)	0.272	1.12 (0.82–1.54)	0.478	
	Senior high	900	346	1.30 (1.00–1.70)	0.054*	1.25 (0.92–1.69)	0.160	
	Higher education	464	218	1.59 (1.19–2.12)	0.002*	1.64 (1.17–2.29)	0.004**	
	Smoking behavior							
	Non-smoker	2490	839	Reference				
	Ex-smoker	346	149	1.28 (1.04–1.57)	0.020*	1.25 (0.96–1.62)	0.093	
	Active smoker	737	340	1.37 (1.18–1.60)	0.000*	1.15 (0.93–1.43)	0.198	
	Active days missed in a month							
	0	1330	497	Reference		Not Included		
	1–7	1690	614	0.97 (0.85–1.12)	0.690			
	>7	550	216	1.05 (0.87–1.27)	0.605			
	Current self-rated health status							
	Very healthy	341	81	Reference				
	Somewhat healthy	1635	612	1.58 (1.22–2.04)	0.001*	1.54 (1.18–2.02)	0.002**	
	Somewhat unhealthy	1440	557	1.63 (1.25–2.12)	0.000*	1.87 (1.42–2.45)	0.000**	
	Very unhealthy	157	78	2.09 (1.45–3.01)	0.000*	2.59 (1.76–3.82)	0.000**	
	Took no prescribed medications in the past week	1375	793	2.37 (2.08–2.70)	0.000*	2.49 (2.17–2.85)	0.000**	

Table 2 Characteristics of traditional medicine users (n = 4,901)

The multivariate model was validated by Hosmer–Lemeshow test (χ^2 = 6.960 and p = 0.541) and omnibus test (χ^2 = 285.299 and p = 0.000). By 2014–2015, 1 USD is averagely equivalent to 13,118 IDR

^{*} Univariate analysis statistically significant by p < 0.25

 ** Multivariate analysis statistically significant by $p\,{<}\,0.05$




Fig. 3 Recommendations for improving rational use of traditional medicine

severity staging, length of the disease, and characterization of the traditional medical system types and the forms of medicine used. In the study design aspect, the causality between exposure and outcome variables should be interpreted cautiously since time differences between the variables cannot be considered in the cross-sectional study. However, the national scope of IFLS-5 might make the results of this study applicable to the general Indonesian population. Acceptable missing data can contribute to internal and external validities. Furthermore, we followed international consensus reporting guidelines to provide a systematic and transparent report.

Recommendations

Our study highlights that TM use among chronic diseases can be seen from two sides. First, it can exacerbate the potential irrational use of medicine due to nonadherence, lack of scientific evidence, and unregulated use. Second, TM can be potentially developed as an accessible alternative treatment for chronic disease patients. Therefore, several recommendations to optimize TM use can be considered that involve three essential aspects, i.e., patient, healthcare provider, and healthcare system (Fig. 3).

Firstly, educating patients with chronic diseases about the disease and TM should be optimized. It requires medical practitioners to have a more patient-centered approach by addressing patients' issues and concerns regarding their chronic diseases and TM use related to those concerns. Furthermore, it also requires further improvements in access to quality healthcare to allow healthcare professionals to monitor TM use and prevent its potential irrationalities.

Secondly, medical practitioners should have the cultural knowledge to identify TM commonly used in chronic diseases and its efficacy, safety, and interaction. Further cultural sensitivity is also needed in addressing issues that might emerge with patients' concerns.

Thirdly, the system and practice of TM should be formalized to the extent possible while preserving its cultural values. Further research and standardization on TM should be performed to provide a consistent framework, ensure safety and efficacy, and enable patients to make well-informed decisions about their treatment. Providing scientific evidence can also increase the acceptance and use of TM in the formal medical system, allowing the integration of TM use into the formal healthcare system.

Conclusions

TM is still widely used for the treatment of various chronic diseases in Indonesia, indicating its potential for further development. However, nonadherence and uncontrolled TM use indicate potential issues of its irrational use. Therefore, further development of strategies to optimize TM use in Indonesia is needed.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12906-023-03947-4.

Additional file 1: Table S1. Operational definition of study. Table S2. STROBE statement checklist for cross-sectional study. Table S3. Variance Inflation Factor (VIF) of variables.

Acknowledgements

We express our deep gratitude to Andini Putri Atika, Muhamad Diva Kafila Raudya, Pandu Sujiwo Kusumo, Viona Mahardika Harjuni, Yuviniar Ekawati, and other friends of LPPMD Universitas Padjadjaran for discussions and insight into the process of this research.

Authors' contributions

I.S.P. conceived the idea and study design. K.A. and I.S.P. wrote the first draft. M.A.A.P. collected the data. K.A., I.S.P., R.M.F., Y.F.N., and M.A.A.P. analyzed and interpreted the data. All authors have critically reviewed the findings and approved the final manuscript.

Funding

This study was supported by internal funding from Universitas Padjadjaran 2022. The funder had no role nor influence in the development and analysis of this study. The IFLS-5 project received funding from the National Institute of Aging (NIA), grant 2R01 AG26676; the National Institute for Child Health and Human Development (NICHD), grant 2R01 HD050764-05A1; World Bank, Indonesia; GRM International; and the Department of Foreign Affairs and Trade, Government of Australia [50].

Availability of data and materials

The IFLS-5 dataset used in this study is available at https://www.rand.org/wellbeing/social-and-behavioral-policy/data/FLS/IFLS/access.html.

Declarations

Ethics approval and consent to participate

The IFLS-5 survey obtained ethical approval from the Institutional Review Boards of RAND in the United States and Universitas Gadjah Mada in Indonesia [48]. Consent for participation in the IFLS-5 study was obtained from all subjects and handled by the parties conducting the IFLS-5 study. We followed the principle of the Declaration of Helsinki in using the IFLS-5 database [49].

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 21 December 2022 Accepted: 4 April 2023 Published online: 14 April 2023

References

- 1. Zheng H, George LK. Does medical expansion improve population health? J Health Soc Behav. 2018;59:113–32.
- 2. World Health Organization. Global report on traditional and complementary medicine. Geneva: World Health Organization. 2019
- Rashrash M, Schommer JC, Brown LM. Prevalence and predictors of herbal medicine use among adults in the United States. J Patient Exp. 2017;4:108–13.
- van Andel T, Carvalheiro LG. Why urban citizens in developing countries use traditional medicines: the case of suriname. Evid Based Complement Altern Med. 2013;2013:1–13.
- Lam CS, Koon HK, Chung VCH, Cheung YT. A public survey of traditional, complementary and integrative medicine use during the COVID-19 outbreak in Hong Kong. PLoS One. 2021;16:e0253890.
- Aprilio K, Wilar G. Emergence of ethnomedical COVID-19 treatment: a literature review. Infect Drug Resist. 2021;14:4277–89.
- World Health Organization. Traditional medicine. 2013. https://apps.who. int/gb/ebwha/pdf_files/EB134/B134_24-en.pdf. Accessed 19 Sep 2021.
- 8. Oberoi S, Chaudhary N, Patnaik S, Singh A. Understanding health seeking behavior. J Fam Med Prim Care. 2016;5:463.
- Widayanti AW, Green JA, Heydon S, Norris P. Health-seeking behavior of people in indonesia: a narrative review. J Epidemiol Glob Health. 2020;10:6.
- Sudhinaraset M, Ingram M, Lofthouse HK, Montagu D. What is the role of informal healthcare providers in developing countries? A systematic review. PLoS One. 2013;8:e54978.
- Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014. https://doi.org/10.3389/fphar.2013.00177
- Elfahmi WHJ, Kayser O. Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use. J Herb Med. 2014;4:51–73.
- Handayani L, Suparto H, Suprapto A. Traditional system of medicine in Indonesia. In: Chaudhury RR, Rafei UM, editors. Tradit. Med. Asia. New Delhi: World Health Organization; 2001. p. 47–68.
- Setditjen Farmalkes. Penggunaan Jamu untuk Meningkatkan Derajat Kesehatan Masyarakat. In: Kementeri. Kesehat. Republik Indones.

2022. https://farmalkes.kemkes.go.id/2022/06/penggunaan-jamu-untukmeningkatkan-derajat-kesehatan-masyarakat/. Accessed 18 Sep 2022.

- Badan Pengawas Obat dan Makanan. Peraturan Badan Pengawas Obat dan Makanan nomor 32 tahun 2019 tentang Persyaratan Keamanan dan Mutu Obat Tradisional. 2019.
- Siswanto B, Setiawati S, Sumantri Riyanto O. Juridical aspects of complementary traditional medicine In Indonesia. Int J Educ Res Soc Sci. 2022;3:468–75.
- 17. Ministry of Health Republic of Indonesia. Peraturan Menteri Kesehatan Republik Indonesia nomor 007 tahun 2012 tentang Resgistrasi Obat Tradisional. 2012.
- Government of Indonesia. Peraturan Pemerintah Republik Indonesia nomor 103 tahun 2014 tentang Pelayanan Kesehatan Tradisional. 2014.
- Pejcic AV, Jakovljevic MB. Economic impact of traditional medicine practice worldwide. Tradit Med Res. 2017;2:60–74.
- Santoso SB, Lutfiyati H, Kusuma TM. Pemberdayaan Potensi Masyarakat Melalui Pengelolaan Kebun Tanaman Obat Keluarga. Community Empower. 2021;6:391–7.
- 21. Xu S, Levine M. Medical residents' and students' attitudes towards herbal medicines: a pilot study. Can J Clin Pharmacol. 2008;15:e1-4.
- Hilal M, Hilal S. Knowledge, attitude, and utilization of herbal medicines by physicians in the Kingdom of Bahrain: a cross-sectional study. J Assoc Arab Univ Basic Appl Sci. 2017;24:325–33.
- Alzahrani SH, Bashawri J, Salawati EM, Bakarman MA. Knowledge and attitudes towards complementary and alternative medicine among senior medical students in King Abdulaziz University Saudi Arabia. Evid Based Complement Altern Med. 2016;2016:9370721.
- Shelley BM, Sussman AL, Williams RL, Segal AR, Crabtree BF. "They don't ask me so i don't tell them": patient-clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med. 2009;7:139–47.
- Kautsar AP, Ayunovani FSM, Surahman E. The influence of demographic, social system, communication system, and herbal characteristics on purchase decisions of herbal medicine in Indonesia. J Econ Bus Manag. 2016;4:235–8.
- Pengpid S, Peltzer K. Utilization of traditional and complementary medicine in Indonesia: results of a national survey in 2014–15. Complement Ther Clin Pract. 2018;33:156–63.
- Rahayu YYS, Araki T, Rosleine D. Factors affecting the use of herbal medicines in the universal health coverage system in Indonesia. J Ethnopharmacol. 2020;260:112974.
- Siswati T, Paramashanti BA, Rialihanto MP, Waris L. Epidemiological transition in indonesia and its prevention: a narrative review. J Complement Altern Med Res. 2022;18:50–60.
- Centers for Disease Control and Prevention. About Chronic Diseases. In: Natl. Cent. Chronic Dis. Prev. Heal. Promot. 2022. https://www.cdc.gov/ chronicdisease/about/index.htm. Accessed 2 Jul 2022.
- Alkaff FF, Illavi F, Salamah S, Setiyawati W, Ramadhani R, Purwantini E, Tahapary DL. The impact of the Indonesian chronic disease management program (PROLANIS) on metabolic control and renal function of type 2 diabetes mellitus patients in primary care setting. J Prim Care Community Health. 2021;12:215013272098440.
- RAND Corporation The IFLS Study Design. In: RAND Soc. Econ. Wellbeing. https://www.rand.org/well-being/social-and-behavioral-policy/ data/FLS/IFLS/study.html. Accessed 2 Jul 2022.
- RAND Corporation About the RAND Corporation. In: RAND Soc. Econ. Well-being. https://www.rand.org/about.html. Accessed 24 Nov 2022.
- Strauss J, Witoelar F, Sikoki B. The Fifth Wave of the Indonesian Family Life Survey (IFLS5): Overview and Field Report. 2016.
- 34. Chrisman NJ. The health seeking process: an approach to the natural history of illness. Cult Med Psychiatry. 1977;1:351–77.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.
- Glanz K. Health Behavior. In: Boslaugh S, editor. Encycl. Epidemiol. Thousand Oaks, CA: SAGE Publications; 2008. p. 459–63.
- 37. Febriyanti RM. Ubar Kampung: indigenous knowledge and practice of medicinal, aromatic and cosmetic (MAC) plants used for the treatment of diabetes mellitus in the Tatar Sunda Region of West Java. Indonesia: Universiteit Leiden; 2021.

- Harahap NA, Khairunnisa K, Tanuwijaya J. Tingkat Pengetahuan Pasien dan Rasionalitas Swamedikasi di Tiga Apotek Kota Panyabungan. J Sains Farm Klin. 2017;3:186–92.
- Hoenders HJR, Willgeroth FC, Appelo MT. Western and alternative medicine: a comparison of paradigms and methods. J Altern Complement Med. 2008;14:894–6.
- 40. Young JT. Illness behaviour: a selective review and synthesis. Sociol Heal Illn. 2004;26:1–31.
- Bhasin V. Medical Anthropology: A Review. Stud Ethno-Medicine. 2007;1:1–20.
- Santos-Marquez F, Gunawan AB, Mendez C. Regional income disparities, distributional convergence, and spatial effects: evidence from Indonesian regions 2010–2017. GeoJournal. 2022;87:2373–91.
- Laksono AD, Wulandari RD, Soedirham O. Urban and Rural Disparities in Hospital Utilization among Indonesian Adults. Iran J Public Health. 2019;48:247–55.
- Mulyanto J, Kunst AE, Kringos DS. Geographical inequalities in healthcare utilisation and the contribution of compositional factors: a multilevel analysis of 497 districts in Indonesia. Health Place. 2019;60:102236.
- Humas BPJS Kesehatan. BPJS Kesehatan Berbagi Pengalaman dengan India Capai UHC. 2021. https://bpjs-kesehatan.go.id/bpjs/post/read/ 2021/2050/BPJS-Kesehatan-Berbagi-Pengalaman-dengan-India-Capai-UHC. Accessed 11 Aug 2022.
- Leslie C. Medical pluralism in world perspective [1]. Soc Sci Med Part B Med Anthropol. 1980;14:191–5.
- Iskandarsyah A, de Klerk C, Suardi DR, Sadarjoen SS, Passchier J. Consulting a traditional healer and negative illness perceptions are associated with non-adherence to treatment in Indonesian women with breast cancer. Psychooncology. 2014;23:1118–24.
- Sato A. Does socio-economic status explain use of modern and traditional health care services? Soc Sci Med. 2012;75:1450–9.
- Ahmad FA. Analisis penggunaan jamu untuk pengobatan pada pasien di klinik saintifikasi jamu hortus medicus Tawangmangu Tahun 2012. Depok: Universitas Indonesia; 2012.
- RAND Corporation IFLS Project Teams and Funding. In: RAND Soc. Econ. Well-being. https://www.rand.org/well-being/social-and-behavioralpolicy/data/FLS/IFLS/teamfund.html. Accessed 5 Sep 2022.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

